Literature DB >> 16723846

Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases.

Mehsati Herawi1, Jonathan I Epstein.   

Abstract

Specialized stromal tumors of the prostate encompass stromal sarcoma and stromal tumors of uncertain malignant potential (STUMP). As a result of their relative rarity and lack of long-term follow-up, the prognosis of STUMP is unclear. We studied 50 cases of STUMP and stromal sarcoma with regard to their clinical presentation and follow-up. Patients ranged in age from 27 to 83 years (mean 58 years). The major presenting signs and symptoms were urinary obstructive symptoms (n=25), abnormal digital rectal exam (n=15), hematuria (n=7), hematospermia (n=1), and rectal dysfunction/fullness (n=3). An elevated prostate-specific antigen was either the sole or a compounding rationale for initial urologic examination and prostate biopsy in a subgroup of patients (n=11). The histology in the 36 cases of STUMP not associated with sarcoma were as follows: 25 composed of stroma with scattered cytologically atypical cells associated with benign glands; 8 resembling glandular-stromal hyperplasia but with hypercellular stroma; 6 with extensive myxoid stroma; and 1 with phyllodes pattern. Four of these cases had mixed patterns. Seven cases of STUMP were associated with sarcoma, either concurrently or subsequently. In another 7 cases, pure sarcomas were encountered: 3 low grade (LG) and 4 high grade (HG). In 19 STUMPs, the location of the lesion was determinable: 10 cases arose in the peripheral zone, 7 cases were located in the transition zone, and 2 cases seemed to involve both zones. In 3 of these cases, tumors were adherent to the rectum at the time of resection. There was no evidence of progression of disease for 14 STUMPs after biopsy, TUR, or enucleation where follow-up ranged from 0.3 to 14 years (mean 4.9 years). Five cases of STUMP showed local tumor growth: 1 case increased in size from 6 to 7.5 cm in 3 years and 4 cases recurred frequently necessitating multiple TURs of the prostate (n=2, n=3, n=3, n=3) over 1.1, 2, 7, and 8 years, respectively. Fourteen patients with STUMP underwent radical prostatectomy (RP) soon after diagnosis; of these, 12 were organ confined where the tumor size ranged from 0.7 to 7.5 cm (mean 2.7 cm); 2 cases with a history of a 28 g TUR and a 275 g enucleation showed no residual tumor in the RP specimen. Three cases were lost to follow-up. The histologic subtypes of STUMP did not correlate with the clinical behavior or likelihood of being associated with sarcoma. Two of the LG sarcomas locally invaded around the seminal vesicle, yet all of the LG sarcomas with follow-up were free of disease at 3, 13, 24, 25, 30, and 36 months. Of the 6 HG sarcomas with follow-up, 3 were free of disease at 3, 17, and 72 months. One man was alive with metastasis to the lung 10 months after RP, 1 man was alive at 280 months with multiple metastases, and another died of disease at 115 months. STUMPs can recur frequently, occur at a young age, often involve the peripheral zone where they can be adherent to the rectum requiring its removal, and can be associated with stromal sarcoma. Although STUMPs can be histologically misdiagnosed as nodular hyperplasia, it is important to recognize that these are neoplasms with unique local morbidity and malignant potential. Whereas LG stromal sarcomas can locally invade, HG sarcomas can metastasize and lead to death.

Entities:  

Mesh:

Year:  2006        PMID: 16723846     DOI: 10.1097/00000478-200606000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  33 in total

1.  MRI findings of prostate stromal tumour of uncertain malignant potential: a case report.

Authors:  V F Muglia; G Saber; G Maggioni; A J C Monteiro
Journal:  Br J Radiol       Date:  2011-10       Impact factor: 3.039

2.  [Stromal tumor of the prostate of uncertain malignant potential. A diagnostic rarity].

Authors:  N Nikolov; T Kramm; G Haroske; B Gieseler; F Steinbach
Journal:  Urologe A       Date:  2008-06       Impact factor: 0.639

3.  CT Imaging Findings of Metastatic Spindle Cell Sarcoma of Prostate: A Case Report and Review of the Literature.

Authors:  Berhan Pirimoglu; David J Vining
Journal:  Eurasian J Med       Date:  2014-08-26

Review 4.  Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Authors:  Douglas W Strand; Daniel N Costa; Franto Francis; William A Ricke; Claus G Roehrborn
Journal:  Differentiation       Date:  2017-08-04       Impact factor: 3.880

5.  A case of laparoscopic radical prostatectomy for a prostatic stromal tumor of uncertain malignant potential.

Authors:  Kyung Won Kwak; Dae Jin Jo; Eun Hee Lee; Dong Soo Ryu; Tae Hee Oh
Journal:  Korean J Urol       Date:  2011-08-22

6.  Two different surgical approaches for prostatic stromal sarcoma: robot-assisted laparoscopic radical prostatectomy and open radical cysto-prostatectomy with ileal conduit.

Authors:  Seock Hwan Choi; Tae-Hwan Kim; Ghil Suk Yoon; Sung Kwang Chung; Bup Wan Kim; Tae Gyun Kwon
Journal:  Korean J Urol       Date:  2014-09-05

7.  Complex cellular composition of solitary fibrous tumor of the prostate.

Authors:  Mehrnaz Gharaee-Kermani; Rohit Mehra; Dan R Robinson; John T Wei; Jill A Macoska
Journal:  Am J Pathol       Date:  2014-01-13       Impact factor: 4.307

8.  A rare benign genitourinary tumor in a Japanese male: urinary retention owing to aggressive angiomyxoma of the prostate.

Authors:  Yugo Sawada; Fumio Ito; Hayakazu Nakazawa; Nobuhiko Tsushima; Hikaru Tomoe; Motohiko Aiba
Journal:  Rare Tumors       Date:  2010-03-31

9.  [Metastazation into the seminal vesicles due to primary goblet cell carcinoid of the vermiform appendix. An unusual diagnostic procedure of a seminal vesicle tumor].

Authors:  T Gramann; L Matter; D Pfofe; R Flury; P Jaeger
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

Review 10.  Imaging of non-epithelial neoplasms of the prostate.

Authors:  Pankaj Nepal; Arpit Nagar; Sree Harsha Tirumani; Vijayanadh Ojili
Journal:  Abdom Radiol (NY)       Date:  2020-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.